Exploring the antitumor effect of virus in malignant glioma

Drugs of the Future

Volumn 40, Issue 11, 2015, Pages 739-749

  Saha, D ^a   Ahmed, S S ^a   Rabkin, S D ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Glioblastoma; Glioma; Malignant neoplasms; Oncolytic virus; Virotherapy

Indexed keywords

HSV 1716; LONTUCIREV; ONCOLYTIC VIRUS; PELAREOREP; TALIMOGENE LAHERPAREPVEC; VOCIMAGENE AMIRETROREPVEC;

ADENOVIRIDAE; ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; GLIOBLASTOMA; HERPES SIMPLEX VIRUS; HUMAN; MEASLES VIRUS; MYXOMA VIRUS; NEWCASTLE DISEASE VIRUS; NONHUMAN; ONCOLYTIC VIROTHERAPY; PARVOVIRIDAE; POLIOMYELITIS VIRUS; REOVIRIDAE; RETROVIRIDAE; REVIEW; VESICULOVIRUS;

EID: 84983440914     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2015.040.11.2383070     Document Type: Review

References (139)

1. Carlsson, S.K., Brothers, S.P., Wahlestedt, C. Emerging treatment strategies for glioblastoma multiforme. EMBO Mol Med 2014, 6(11): 1359-70.
2. Ostrom, Q.T., Gittleman, H., Liao, P. et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol 2014, 16(Suppl. 4): Iv1-63.
3. Louis, D.N., Ohgaki, H., Wiestler, O.D. et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007, 114(2): 97-109.
4. Ohgaki, H., Kleihues, P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007, 170(5): 1445-53.
5. Wen, P.Y., Kesari, S. Malignant gliomas in adults. N Engl J Med 2008, 359(5): 492-507.
6. Parsons, D.W., Jones, S., Zhang, X. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321(5897): 1807-12.
7. Sturm, D., Bender, S., Jones, D.T. et al. Paediatric and adult glioblastoma: Multiform (epi)genomic culprits emerge. Nat Rev Cancer 2014, 14(2): 92-107.
8. Louis, D.N., Perry, A., Burger, P. et al. International Society Of Neuropathology-Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 2014, 24(5): 429-35.
9. Dirks, P.B. Brain tumor stem cells: The cancer stem cell hypothesis writ large. Mol Oncol 2010, 4(5): 420-30.
10. Lathia, J.D., Mack, S.C., Mulkearns-Hubert, E.E., Valentim, C.L., Rich, J.N. Cancer stem cells in glioblastoma. Genes Dev 2015, 29(12): 1203-17.
11. Bao, S., Wu, Q., McLendon, R.E. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444(7120): 756-60.
12. Wang, J., Wakeman, T.P., Lathia, J.D. et al. Notch promotes radioresistance of glioma stem cells. Stem Cells 2010, 28(1): 17-28.
13. Bhat, K.P., Balasubramaniyan, V., Vaillant, B. et al. Mesenchymal differentiation mediated by NF-kappaB promotes radiation resistance in glioblastoma. Cancer Cell 2013, 24(3): 331-46.
14. Venere, M., Hamerlik, P., Wu, Q. et al. Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells. Cell Death Differ 2014, 21(2): 258-69.
15. Kim, S.H., Joshi, K., Ezhilarasan, R. et al. EZH2 protects glioma stem cells from radiation-induced cell death in a MELK/FOXM1-dependent manner. Stem Cell Reports 2015, 4(2): 226-38.
16. Cho, D.Y., Lin, S.Z., Yang, W.K. et al. Targeting cancer stem cells for treatment of glioblastoma multiforme. Cell Transplant 2013, 22(4): 731-9.
17. Tanaka, S., Louis, D.N., Curry, W.T., Batchelor, T.T., Dietrich, J. Diagnostic and therapeutic avenues for glioblastoma: No longer a dead end? Nat Rev Clin Oncol 2013, 10(1): 14-26.
18. Prados, M.D., Byron, S.A., Tran, N.L. et al. Toward precision medicine in glioblastoma: The promise and the challenges. Neuro Oncol 2015, 17(8): 1051-63.
19. Preusser, M., de Ribaupierre, S., Wohrer, A., Erridge, S.C., Hegi, M., Weller, M., Stupp, R. Current concepts and management of glioblastoma. Ann Neurol 2011, 70(1): 9-21.
20. Perng, P., Lim, M. Immunosuppressive mechanisms of malignant gliomas: Parallels at non-CNS sites. Front Oncol 2015, 5: 153.
21. Russell, S.J., Peng, K.W., Bell, J.C. Oncolytic virotherapy. Nat Biotechnol 2012, 30(7): 658-70.
22. Martuza, R.L., Malick, A., Markert, J.M., Ruffner, K.L., Coen, D.M. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991, 252(5007): 854-6.
23. Auffinger, B., Ahmed, A.U., Lesniak, M.S. Oncolytic virotherapy for malignant glioma: Translating laboratory insights into clinical practice. Front Oncol 2013, 3: 32.
24. Murphy, A.M., Rabkin, S.D. Current status of gene therapy for brain tumors. Transl Res 2013, 161(4): 339-54.
25. Kaufmann, J.K., Chiocca, E.A. Glioma virus therapies between bench and bedside. Neuro Oncol 2014, 16(3): 334-51.
26. Angarita, F.A., Acuna, S.A., Ottolino-Perry, K., Zerhouni, S., McCart, J.A. Mounting a strategic offense: Fighting tumor vasculature with oncolytic viruses. Trends Mol Med 2013, 19(6): 378-92.
27. Chiocca, E.A., Rabkin, S.D. Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res 2014, 2(4): 295-300.
28. Wollmann, G., Ozduman, K., van den Pol, A.N. Oncolytic virus therapy for glioblastoma multiforme: Concepts and candidates. Cancer J 2012, 18(1): 69-81.
29. Whitley, R.J. Herpes simplex encephalitis: Adolescents and adults. Antiviral Res 2006, 71(2-3): 141-8.
30. Peters, C., Rabkin, S.D. Designing herpes viruses as oncolytics. Molecular Therapy - Oncolytics 2015, 2: 15010.
31. Ning, J., Wakimoto, H. Oncolytic herpes simplex virus-based strategies: Toward a breakthrough in glioblastoma therapy. Front Microbiol 2014, 5: 303.
32. Cheema, T.A., Wakimoto, H., Fecci, P.E. et al. Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proc Natl Acad Sci U S A 2013, 110(29): 12006-11.
33. Advani, S.J., Markert, J.M., Sood, R.F. et al. Increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of HSV-1. Gene Ther 2011, 18(11): 1098-102.
34. Aghi, M., Rabkin, S., Martuza, R.L. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J Natl Cancer Inst 2006, 98(1): 38-50.
35. Kanai, R., Rabkin, S.D., Yip, S. et al. Oncolytic virus-mediated manipulation of DNA damage responses: Synergy with chemotherapy in killing glioblastoma stem cells. J Natl Cancer Inst 2012, 104(1): 42-55.
36. Zhang, W., Fulci, G., Buhrman, J.S. et al. Bevacizumab with angiostatinarmed oHSV increases antiangiogenesis and decreases bevacizumabinduced invasion in U87 glioma. Mol Ther 2012, 20(1): 37-45.
37. Kanai, R., Wakimoto, H., Martuza, R.L., Rabkin, S.D. A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells. Clin Cancer Res 2011, 17(11): 3686-96.
38. Kanai, R., Rabkin, S.D. Combinatorial strategies for oncolytic herpes simplex virus therapy of brain tumors. CNS Oncol 2013, 2(2): 129-42.
39. Zhang, W., Fulci, G., Wakimoto, H. et al. Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models. Neoplasia 2013, 15(6): 591-9.
40. Barnard, Z., Wakimoto, H., Zaupa, C. et al. Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma. Neurosurgery 2012, 71(3): 741-8.
41. Tamura, K., Wakimoto, H., Agarwal, A.S. et al. Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors. Mol Ther 2013, 21(1): 68-77.
42. Cheema, T.A., Kanai, R., Kim, G.W., Wakimoto, H., Passer, B., Rabkin, S.D., Martuza, R.L. Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts. Clin Cancer Res 2011, 17(23): 7383-93.
43. Andtbacka, R.H., Kaufman, H.L., Collichio, F. et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 2015, 33(25): 2780-8.
44. Wakimoto, H., Kesari, S., Farrell, C.J. et al. Human glioblastoma-derived cancer stem cells: Establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res 2009, 69(8): 3472-81.
45. Kanai, R., Zaupa, C., Sgubin, D., Antoszczyk, S.J., Martuza, R.L., Wakimoto, H., Rabkin, S.D. Effect of gamma34.5 deletions on oncolytic herpes simplex virus activity in brain tumors. J Virol 2012, 86(8): 4420-31.
46. Todo, T., Martuza, R.L., Rabkin, S.D., Johnson, P.A. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci U S A 2001, 98(11): 6396-401.
47. Roth, J.C., Cassady, K.A., Cody, J.J. et al. Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates. Hum Gene Ther Clin Dev 2014, 25(1): 16-27.
48. Lasner, T.M., Tal-Singer, R., Kesari, S., Lee, V.M., Trojanowski, J.Q., Fraser, N.W. Toxicity and neuronal infection of a HSV-1 ICP34.5 mutant in nude mice. J Neurovirol 1998, 4(1): 100-5.
49. Harrow, S., Papanastassiou, V., Harland, J. et al. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: Safety data and long-term survival. Gene Ther 2004, 11(22): 1648-58.
50. Rampling, R., Cruickshank, G., Papanastassiou, V. et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 2000, 7(10): 859-66.
51. Papanastassiou, V., Rampling, R., Fraser, M. et al. The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: A proof of principle study. Gene Ther 2002, 9(6): 398-406.
52. Markert, J.M., Medlock, M.D., Rabkin, S.D. et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial. Gene Ther 2000, 7(10): 867-74.
53. Markert, J.M., Liechty, P.G., Wang, W. et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther 2009, 17(1): 199-207.
54. Markert, J.M., Razdan, S.N., Kuo, H.C. et al. A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Mol Ther 2014, 22(5): 1048-55.
55. Jiang, H., Gomez-Manzano, C., Rivera-Molina, Y., Lang, F.F., Conrad, C.A., Fueyo, J. Oncolytic adenovirus research evolution: From cell-cycle checkpoints to immune checkpoints. Curr Opin Virol 2015, 13: 33-9.
56. Chiocca, E.A., Abbed, K.M., Tatter, S. et al. A phase I open-label, doseescalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 2004, 10(5): 958-66.
57. Fueyo, J., Gomez-Manzano, C., Alemany, R. et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000, 19(1): 2-12.
58. Network, C.G.A.R. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455(7216): 1061-8.
59. Alonso, M.M., Cascallo, M., Gomez-Manzano, C. et al. ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo. Cancer Res 2007, 67(17): 8255-63.
60. Fueyo, J., Alemany, R., Gomez-Manzano, C. et al. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst 2003, 95(9): 652-60.
61. Jiang, H., Clise-Dwyer, K., Ruisaard, K.E. et al. Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model. PLoS One 2014, 9(5): E97407.
62. Jiang, H., Gomez-Manzano, C., Aoki, H. et al. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: Role of autophagic cell death. J Natl Cancer Inst 2007, 99(18): 1410-4.
63. Piao, Y., Jiang, H., Alemany, R. et al. Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity. Cancer Gene Ther 2009, 16(3): 256-65.
64. Ulasov, I.V., Zhu, Z.B., Tyler, M.A. et al. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Hum Gene Ther 2007, 18(7): 589-602.
65. Nandi, S., Ulasov, I.V., Rolle, C.E., Han, Y., Lesniak, M.S. A chimeric adenovirus with an Ad 3 fiber knob modification augments glioma virotherapy. J Gene Med 2009, 11(11): 1005-11.
66. Brouwer, E., Havenga, M.J., Ophorst, O. et al. Human adenovirus type 35 vector for gene therapy of brain cancer: Improved transduction and bypass of pre-existing anti-vector immunity in cancer patients. Cancer Gene Ther 2007, 14(2): 211-9.
67. Angelova, A.L., Geletneky, K., Nuesch, J.P., Rommelaere, J. Tumor selectivity of oncolytic Parvoviruses: From in vitro and animal models to cancer patients. Front Bioeng Biotechnol 2015, 3: 55.
68. Luo, Y., Qiu, J. Human parvovirus B19: A mechanistic overview of infection and DNA replication. Future Virol 2015, 10(2): 155-67.
69. Rommelaere, J., Geletneky, K., Angelova, A.L. et al. Oncolytic parvoviruses as cancer therapeutics. Cytokine Growth Factor Rev 2010, 21(2-3): 185-95.
70. Herrero, Y.C.M., Cornelis, J.J., Herold-Mende, C., Rommelaere, J., Schlehofer, J.R., Geletneky, K. Parvovirus H-1 infection of human glioma cells leads to complete viral replication and efficient cell killing. Int J Cancer 2004, 109(1): 76-84.
71. Geletneky, K., Kiprianova, I., Ayache, A. et al. Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models. Neuro Oncol 2010, 12(8): 804-14.
72. Moehler, M.H., Zeidler, M., Wilsberg, V. et al. Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells. Hum Gene Ther 2005, 16(8): 996-1005.
73. Geletneky, K., Huesing, J., Rommelaere, J. et al. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol. BMC Cancer 2012, 12: 99.
74. Maitra, R., Ghalib, M.H., Goel, S. Reovirus: A targeted therapeutic- progress and potential. Mol Cancer Res 2012, 10(12): 1514-25.
75. Thirukkumaran, C., Morris, D.G. Oncolytic viral therapy using reovirus. Methods Mol Biol 2015, 1317: 187-223.
76. Coffey, M.C., Strong, J.E., Forsyth, P.A., Lee, P.W. Reovirus therapy of tumors with activated Ras pathway. Science 1998, 282(5392): 1332-4.
77. Wilcox, M.E., Yang, W., Senger, D. et al. Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst 2001, 93(12): 903-12.
78. Yang, W.Q., Lun, X., Palmer, C.A. et al. Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: Racine and nonhuman primates. Clin Cancer Res 2004, 10(24): 8561-76.
79. Alloussi, S.H., Alkassar, M., Urbschat, S., Graf, N., Gartner, B. All reovirus subtypes show oncolytic potential in primary cells of human high-grade glioma. Oncol Rep 2011, 26(3): 645-9.
80. van den Hengel, S.K., Balvers, R.K., Dautzenberg, I.J. et al. Heterogeneous reovirus susceptibility in human glioblastoma stem-like cell cultures. Cancer Gene Ther 2013, 20(9): 507-13.
81. Forsyth, P., Roldan, G., George, D. et al. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther 2008, 16(3): 627-32.
82. Kicielinski, K.P., Chiocca, E.A., Yu, J.S., Gill, G.M., Coffey, M., Markert, J.M. Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults. Mol Ther 2014, 22(5): 1056-62.
83. Nakamura, T., Saito, R., Sugiyama, S., Sonoda, Y., Kumabe, T., Tominaga, T. Local convection-enhanced delivery of chemotherapeutic agent transiently opens blood-brain barrier and improves efficacy of systemic chemotherapy in intracranial xenograft tumor model. Cancer Lett 2011, 310(1): 77-83.
84. Chakrabarty, R., Tran, H., Selvaggi, G., Hagerman, A., Thompson, B., Coffey, M. The oncolytic virus, pelareorep, as a novel anticancer agent: A review. Invest New Drugs 2015, 33(3): 761-74.
85. Fournier, P., Schirrmacher, V. Oncolytic Newcastle disease virus as cutting edge between tumor and host. Biology (Basel) 2013, 2(3): 936-75.
86. Lam, H.Y., Yeap, S.K., Rasoli, M., Omar, A.R., Yusoff, K., Suraini, A.A., Alitheen, N.B. Safety and clinical usage of newcastle disease virus in cancer therapy. J Biomed Biotechnol 2011, 2011: 718710.
87. Zulkifli, M.M., Ibrahim, R., Ali, A.M. et al. Newcastle diseases virus strain V4UPM displayed oncolytic ability against experimental human malignant glioma. Neurol Res 2009, 31(1): 3-10.
88. Koks, C.A., Garg, A.D., Ehrhardt, M. et al. Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death. Int J Cancer 2015, 136(5): E313-25.
89. Buijs, P.R., van Amerongen, G., van Nieuwkoop, S. et al. Intravenously injected Newcastle disease virus in non-human primates is safe to use for oncolytic virotherapy. Cancer Gene Ther 2014, 21(11): 463-71.
90. Freeman, A.I., Zakay-Rones, Z., Gomori, J.M. et al. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther 2006, 13(1): 221-8.
91. Reuter, D., Schneider-Schaulies, J. Measles virus infection of the CNS: Human disease, animal models, and approaches to therapy.Med Microbiol Immunol 2010, 199(3): 261-71.
92. Msaouel, P., Opyrchal, M., Domingo Musibay, E., Galanis, E. Oncolytic measles virus strains as novel anticancer agents. Expert Opin Biol Ther 2013, 13(4): 483-502.
93. Allen, C., Opyrchal, M., Aderca, I. et al. Oncolytic measles virus strains have significant antitumor activity against glioma stem cells. Gene Ther 2013, 20(4): 444-9.
94. Allen, C., Vongpunsawad, S., Nakamura, T. et al. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. Cancer Res 2006, 66(24): 11840-50.
95. Allen, C., Paraskevakou, G., Iankov, I. et al. Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity. Mol Ther 2008, 16(9): 1556-64.
96. Phuong, L.K., Allen, C., Peng, K.W. et al. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res 2003, 63(10): 2462-9.
97. Myers, R., Harvey, M., Kaufmann, T.J. et al. Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas. Hum Gene Ther 2008, 19(7): 690-8.
98. Brown, M.C., Gromeier, M. Cytotoxic and immunogenic mechanisms of recombinant oncolytic poliovirus. Curr Opin Virol 2015, 13: 81-5.
99. Gromeier, M., Alexander, L., Wimmer, E. Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants. Proc Natl Acad Sci U S A 1996, 93(6): 2370-5.
100. Gromeier, M., Lachmann, S., Rosenfeld, M.R., Gutin, P.H., Wimmer, E. Intergeneric poliovirus recombinants for the treatment of malignant glioma [see comments]. Proc Natl Acad Sci U S A 2000, 97(12): 6803-8.
101. Ochiai, H., Moore, S.A., Archer, G.E. et al. Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirus. Clin Cancer Res 2004, 10(14): 4831-8.
102. Dobrikova, E.Y., Goetz, C., Walters, R.W. et al. Attenuation of neurovirulence, biodistribution, and shedding of a poliovirus: Rhinovirus chimera after intrathalamic inoculation in Macaca fascicularis. J Virol 2012, 86(5): 2750-9.
103. Nisole, S., Saib, A. Early steps of retrovirus replicative cycle. Retrovirology 2004, 1: 9.
104. Tai, C.K., Kasahara, N. Replication-competent retrovirus vectors for cancer gene therapy. Front Biosci 2008, 13: 3083-95.
105. Tai, C.K., Wang, W.J., Chen, T.C., Kasahara, N. Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma. Mol Ther 2005, 12(5): 842-51.
106. Wang, W., Tai, C.K., Kershaw, A.D., Solly, S.K., Klatzmann, D., Kasahara, N., Chen, T.C. Use of replication-competent retroviral vectors in an immunocompetent intracranial glioma model. Neurosurg Focus 2006, 20(4): E25.
107. Perez, O.D., Logg, C.R., Hiraoka, K. et al. Design and selection of Toca 511 for clinical use: Modified retroviral replicating vector with improved stability and gene expression. Mol Ther 2012, 20(9): 1689-98.
108. Ostertag, D., Amundson, K.K., Lopez Espinoza, F. et al. Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector. Neuro Oncol 2012, 14(2): 145-59.
109. Huang, T.T., Hlavaty, J., Ostertag, D. et al. Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model. Cancer Gene Ther 2013, 20(10): 544-51.
110. Huang, T.T., Parab, S., Burnett, R. et al. Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model. Hum Gene Ther 2015, 26(2): 82-93.
111. Hastie, E., Grdzelishvili, V.Z. Vesicular stomatitis virus as a flexible plat- form for oncolytic virotherapy against cancer. J Gen Virol 2012, 93(Pt 12): 2529-45.
112. Stojdl, D.F., Lichty, B.D., tenOever, B.R. et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003, 4(4): 263-75.
113. Lun, X., Senger, D.L., Alain, T. et al. Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas. J Natl Cancer Inst 2006, 98(21): 1546-57.
114. Muik, A., Stubbert, L.J., Jahedi, R.Z. et al. Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency. Cancer Res 2014, 74(13): 3567-78.
115. Wollmann, G., Drokhlyansky, E., Davis, J.N., Cepko, C., van den Pol, A.N. Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors. J Virol 2015, 89(13): 6711-24.
116. van den Pol, A.N., Davis, J.N. Highly attenuated recombinant vesicular stomatitis virus VSV-12'GFP displays immunogenic and oncolytic activity. J Virol 2013, 87(2): 1019-34.
117. Obuchi, M., Fernandez, M., Barber, G.N. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J Virol 2003, 77(16): 8843-56.
118. Wollmann, G., Rogulin, V., Simon, I., Rose, J.K., van den Pol, A.N. Some attenuated variants of vesicular stomatitis virus show enhanced oncolytic activity against human glioblastoma cells relative to normal brain cells. J Virol 2010, 84(3): 1563-73.
119. Chan, W.M., McFadden, G. Oncolytic Poxviruses. Annu Rev Virol 2014, 1(1): 119-41.
120. Bartee, E., McFadden, G. Human cancer cells have specifically lost the ability to induce the synergistic state caused by tumor necrosis factor plus interferon-beta. Cytokine 2009, 47(3): 199-205.
121. Wang, G., Barrett, J.W., Stanford, M. et al. Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc Natl Acad Sci U S A 2006, 103(12): 4640-5.
122. Lun, X., Yang, W., Alain, T. et al. Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Res 2005, 65(21): 9982-90.
123. Lun, X., Alain, T., Zemp, F.J. et al. Myxoma virus virotherapy for glioma in immunocompetent animal models: Optimizing administration routes and synergy with rapamycin. Cancer Res 2010, 70(2): 598-608.
124. Zemp, F.J., Lun, X., McKenzie, B.A. et al. Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin. Neuro Oncol 2013, 15(7): 904-20.
125. McKenzie, B.A., Zemp, F.J., Pisklakova, A. et al. In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells. Neuro Oncol 2015, 17(8): 1086-94.
126. Kaur, B., Cripe, T.P., Chiocca, E.A. "Buy one get one free": Armed viruses for the treatment of cancer cells and their microenvironment. Curr Gene Ther 2009, 9(5): 341-55.
127. Agarwalla, P., Barnard, Z., Fecci, P., Dranoff, G., Curry, W.T., Jr. Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. J Immunother 2012, 35(5): 385-9.
128. Wainwright, D.A., Chang, A.L., Dey, M. et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res 2014, 20(20): 5290-301.
129. Dias, J.D., Hemminki, O., Diaconu, I. et al. Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. Gene Ther 2012, 19(10): 988-98.
130. Engeland, C.E., Grossardt, C., Veinalde, R. et al. CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. Mol Ther 2014, 22(11): 1949-59.
131. Van Gool, S.W. Brain tumor immunotherapy: What have we learned so far? Front Oncol 2015, 5: 98.
132. Yin, D., Zhai, Y., Gruber, H.E. et al. Convection-enhanced delivery improves distribution and efficacy of tumor-selective retroviral replicating vectors in a rodent brain tumor model. Cancer Gene Ther 2013, 20(6): 336-41.
133. Nakashima, H., Kaur, B., Chiocca, E.A. Directing systemic oncolytic viral delivery to tumors via carrier cells. Cytokine Growth Factor Rev 2010, 21(2- 3): 119-26.
134. Young, J.S., Kim, J.W., Ahmed, A.U., Lesniak, M.S. Therapeutic cell carriers: A potential road to cure glioma. Expert Rev Neurother 2014, 14(6): 651-60.
135. Ahmed, A.U., Thaci, B., Tobias, A.L. et al. A preclinical evaluation of neural stem cell-based cell carrier for targeted antiglioma oncolytic virotherapy. J Natl Cancer Inst 2013, 105(13): 968-77.
136. Duebgen, M., Martinez-Quintanilla, J., Tamura, K., Hingtgen, S., Redjal, N., Wakimoto, H., Shah, K. Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy. J Natl Cancer Inst 2014, 106(6): Dju090.
137. Yong, R.L., Shinojima, N., Fueyo, J. et al. Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res 2009, 69(23): 8932-40.
138. Fulci, G., Breymann, L., Gianni, D. et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci U S A 2006, 103(34): 12873-8.
139. Kolb, E.A., Sampson, V., Stabley, D. et al. A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: A Children's Oncology Group Phase I Consortium report. Pediatr Blood Cancer 2015, 62(5): 751-8.